BioSupply Trends Quarterly logo
Search
Close this search box.

Coming Soon: Dried Plasma for Hemorrhagic Trauma in the Prehospital Setting

Dried Plasma for Hemorrhagic Trauma in the Prehospital Setting

It is now well-established that prehospital transfusion of plasma, with its balanced mix of coagulation proteins, counters the hemodilution and progressive derangement of hemostatic mechanisms caused by crystalloid-based resuscitation, improving the changes of survival in severely bleed trauma victims.

The Promise of COVID-19 Hyperimmune Immune Globulin Therapy

As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.

Secondary Antibody Deficiency

Illustration of immune cell

Demand for IG products has doubled, going from 3 million grams just a decade ago to 7 million grams year-over-year today. What is to account for this increase?